Intrinsic-mediated caspase activation is essential for cardiomyocyte hypertrophy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 43, 2013, Pages

  Putinski, Charis ^a,b   Abdul Ghani, Mohammad ^a,b   Stiles, Rebecca ^a,b   Brunette, Steve ^a   Dick, Sarah A ^a,b   Fernando, Pasan ^b,c,d   Megeney, Lynn A ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^d MDS Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; EFFECTOR CASPASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYOCYTE ENHANCER FACTOR 2;

APOPTOSIS; ARTICLE; CELL FUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART VENTRICLE HYPERTROPHY; IN VIVO STUDY; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

EID: 84886389101     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1315587110     Document Type: Article

References (47)

1. Kolodziejczyk SM, et al. (1999) MEF2 is upregulated during cardiac hypertrophy and is required for normal post-natal growth of the myocardium. Curr Biol 9(20):1203-1206.
2. Liu Q, Chen Y, Auger-Messier M, Molkentin JD (2012) Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res 110(8):1077-1086.
3. Olson EN, Backs J, McKinsey TA (2006) Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation. Novartis Found Symp 274:3-12.
4. Nicol RL, Frey N, Olson EN (2000) From the sarcomere to the nucleus: role of genetics and signaling in structural heart disease. Annu Rev Genomics Hum Genet 1:179-223.
5. Oka T, Komuro I (2008) Molecular mechanisms underlying the transition of cardiac hypertrophy to heart failure. Circ J 72(Suppl A):A13-A16.
6. Dorn GW, 2nd (2009) Having a change of heart: reversing the suicidal proclivities of cardiac myocytes. Trans Am Clin Climatol Assoc 120:189-198.
7. van Berlo JH, Maillet M, Molkentin JD (2013) Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest 123(1):37-45.
8. Jobe LJ, et al. (2009) TNF-alpha inhibition attenuates adverse myocardial remodeling in a rat model of volume overload. Am J Physiol Heart Circ Physiol 297(4): H1462-H1468.
9. Sun M, et al. (2007) Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 115(11):1398-1407.
10. Badorff C, et al. (2002) Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. J Clin Invest 109(3): 373-381.
11. McDermott-Roe C, et al. (2011) Endonuclease G is a novel determinant of cardiac hypertrophy and mitochondrial function. Nature 478(7367):114-118.
12. Abdul-Ghani M, et al. (2011) Wnt11 promotes cardiomyocyte development by caspase-mediated suppression of canonical Wnt signals. Mol Cell Biol 31(1):163-178.
13. Abdul-Ghani M, Megeney LA (2008) Rehabilitation of a contract killer: caSpase-3 directs stem cell differentiation. Cell Stem Cell 2(6):515-516.
14. Fuchs Y, Steller H (2011) Programmed cell death in animal development and disease. Cell 147(4):742-758.
15. Larsen BD, et al. (2010) Caspase 3/caspase-activated DNase promote cell differentiation by inducing DNA strand breaks. Proc Natl Acad Sci USA 107(9):4230-4235.
16. Lee RE, Brunette S, Puente LG, Megeney LA (2010) Metacaspase Yca1 is required for clearance of insoluble protein aggregates. Proc Natl Acad Sci USA 107(30): 13348-13353.
17. Coll KE, Joseph SK, Corkey BE, Williamson JR (1982) Determination of the matrix free Ca2+ concentration and kinetics of Ca2+ efflux in liver and heart mitochondria. J Biol Chem 257(15):8696-8704.
18. Nagendran J, et al. (2008) A dynamic and chamber-specific mitochondrial remodeling in right ventricular hypertrophy can be therapeutically targeted. J Thorac Cardiovasc Surg 136(1):168-178.e3.
19. Garcia R, Thibault G, Cantin M (1987) Correlation between cardiac hypertrophy and plasma levels of atrial natriuretic factor in non-spontaneous models of hypertension in the rat. Biochem Biophys Res Commun 145(1):532-541.
20. Ploner C, Kofler R, Villunger A (2008) Noxa: At the tip of the balance between life and death. Oncogene 27(Suppl 1):S84-S92.
21. Zhuang J, Brady HJ (2006) Emerging role of Mcl-1 in actively counteracting BH3-only proteins in apoptosis. Cell Death Differ 13(8):1263-1267.
22. Ryan CA, et al. (2002) Inhibitor specificity of recombinant and endogenous caspase-9. Biochem J 366(pt 2):595-601.
23. Fuentes-Prior P, Salvesen GS (2004) The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J 384(pt 2):201-232.
24. Clem RJ (2001) Baculoviruses and apoptosis: The good, the bad, and the ugly. Cell Death Differ 8(2):137-143.
25. Zhang CL, et al. (2002) Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110(4):479-488.
26. Escaffit F, et al. (2007) Cleavage and cytoplasmic relocalization of histone deacetylase 3 are important for apoptosis progression. Mol Cell Biol 27(2):554-567.
27. Liu F, Dowling M, Yang XJ, Kao GD (2004) Caspase-mediated specific cleavage of human histone deacetylase 4. J Biol Chem 279(33):34537-34546.
28. Paroni G, et al. (2004) Caspase-dependent regulation of histone deacetylase 4 nuclear-cytoplasmic shuttling promotes apoptosis. Mol Biol Cell 15(6):2804-2818.
29. Montgomery RL, et al. (2008) Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 118(11):3588-3597.
30. Liu IC, Chiu SW, Lee HY, Leu JY (2012) The histone deacetylase Hos2 forms an Hsp42-dependent cytoplasmic granule in quiescent yeast cells. Mol Biol Cell 23(7):1231-1242.
31. Waltregny D, et al. (2005) Histone deacetylase HDAC8 associates with smooth muscle alpha-actin and is essential for smooth muscle cell contractility. FASEB J 19(8):966-968.
32. Gordon JW, Shaw JA, Kirshenbaum LA (2011) Multiple facets of NF-κB in the heart: To be or not to NF-κB. Circ Res 108(9):1122-1132.
33. Lamkanfi M, Declercq W, Vanden Berghe T, Vandenabeele P (2006) Caspases leave the beaten track: caspase-mediated activation of NF-kappaB. J Cell Biol 173(2): 165-171.
34. Rathore N, Matta H, Chaudhary PM (2004) An evolutionary conserved pathway of nuclear factor-kappaB activation involving caspase-mediated cleavage and N-end rule pathway-mediated degradation of IkappaBalpha. J Biol Chem 279(38):39358-39365.
35. Su H, et al. (2005) Requirement for caspase-8 in NF-kappaB activation by antigen receptor. Science 307(5714):1465-1468.
36. Peterson QP, et al. (2009) PAC-1 activates procaspase-3 in vitro through relief of zincmediated inhibition. J Mol Biol 388(1):144-158.
37. Putt KS, et al. (2006) Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol 2(10):543-550.
38. Adams JW, et al. (2000) Cardiomyocyte apoptosis induced by Galphaq signaling is mediated by permeability transition pore formation and activation of the mitochondrial death pathway. Circ Res 87(12):1180-1187.
39. Balakumar P, Singh M (2006) The possible role of caspase-3 in pathological and physiological cardiac hypertrophy in rats. Basic Clin Pharmacol Toxicol 99(6):418-424.
40. Balsam LB, Kofidis T, Robbins RC (2005) Caspase-3 inhibition preserves myocardial geometry and long-term function after infarction. J Surg Res 124(2):194-200.
41. Adams JW, et al. (1998) Enhanced Galphaq signaling: A common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA 95(17): 10140-10145.
42. D'Angelo DD, et al. (1997) Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci USA 94(15):8121-8126.
43. Communal C, et al. (2002) Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci USA 99(9):6252-6256.
44. Fischer U, Jänicke RU, Schulze-Osthoff K (2003) Many cuts to ruin: A comprehensive update of caspase substrates. Cell Death Differ 10(1):76-100.
45. Moretti A, et al. (2002) Essential myosin light chain as a target for caspase-3 in failing myocardium. Proc Natl Acad Sci USA 99(18):11860-11865.
46. Solinet S, Vitale ML (2008) Isoform B of myosin II heavy chain mediates actomyosin contractility during TNFalpha-induced apoptosis. J Cell Sci 121(pt 10):1681-1692.
47. Deedwania PC, Carbajal E (2012) Evidence-based therapy for heart failure. Med Clin North Am 96(5):915-931.